Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
Author: Tasian, S.
Doral, M.
Borowitz, M.
Wood, B.
Chen, I.-M.
Harvey, R.
Gastier-Foster, J.
Willman, C.
Hunger, S.
Mullighan, C.
Loh, M.
Citation: Blood, 2012; 120(4):833-842
Publisher: American Society of Hematology
Issue Date: 2012
ISSN: 0006-4971
Statement of
Sarah K. Tasian, Michelle Y. Doral, Michael J. Borowitz, Brent L. Wood, I-Ming Chen, Richard C. Harvey, Julie M. Gastier-Foster, Cheryl L. Willman, Stephen P. Hunger, Charles G. Mullighan and Mignon L. Loh
Abstract: Adults and children with high-risk CRLF2-rearranged acute lymphoblastic leukemia (ALL) respond poorly to current cytotoxic chemotherapy and suffer unacceptably high rates of relapse, supporting the need to use alternative therapies. CRLF2 encodes the thymic stromal lymphopoietin (TSLP) receptor, which activates cell signaling in normal lymphocytes on binding its ligand, TSLP. We hypothesized that aberrant cell signaling occurs in CRLF2-rearranged ALL and can be targeted by signal transduction inhibitors of this pathway. In a large number of primary CRLF2-rearranged ALL samples, we observed increased basal levels of pJAK2, pSTAT5, and pS6. We thus characterized the biochemical sequelae of CRLF2 and JAK alterations in CRLF2-rearranged ALL primary patient samples via analysis of TSLP-mediated signal transduction. TSLP stimulation of these leukemias further induced robust JAK/STAT and PI3K/mTOR pathway signaling. JAK inhibition abrogated phosphorylation of JAK/STAT and, surprisingly, of PI3K/mTOR pathway members, suggesting an interconnection between these signaling networks and providing a rationale for testing JAK inhibitors in clinical trials. The PI3K/mTOR pathway inhibitors rapamycin, PI103, and PP242 also inhibited activated signal transduction and translational machinery proteins of the PI3K/mTOR pathway, suggesting that signal transduction inhibitors targeting this pathway also may have therapeutic relevance for patients with CRLF2-rearranged ALL and merit further preclinical testing.
Keywords: Tumor Cells, Cultured
Receptors, Cytokine
RNA, Messenger
Blotting, Western
Flow Cytometry
In Situ Hybridization, Fluorescence
Signal Transduction
Cell Proliferation
Gene Rearrangement
Point Mutation
STAT5 Transcription Factor
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Phosphatidylinositol 3-Kinases
TOR Serine-Threonine Kinases
Real-Time Polymerase Chain Reaction
Rights: © 2012 by The American Society of Hematology
DOI: 10.1182/blood-2011-12-389932
Published version:
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.